Antonella Meloni1, Caterina Borgna-Pignatti2, Giovanni Carlo Del Vecchio3, Maria Antonietta Romeo4, Maria Rita Gamberini5, Federico Bonetti6, Maria Giovanna Neri1, Elisabetta Chiodi7, Vincenzo Positano1, and Alessia Pepe1
1Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, 2Università di Ferrara, Ferrara, Italy, 3Uiversity of Bari, Bari, Italy, 4University of Catania, Catania, Italy, 5Arcispedale "S.Anna", Ferrara, Italy, 6Policlinic Foundation San Matteo IRCCS, Pavia, Italy, 7Arcispedale “S. Anna”, Ferrara, Italy
Synopsis
The introduction of T2* CMR for the reproducible and non-invasive assessment of myocardial iron overload reduced the likelihood of
developing decompensated cardiac failure, allowing the reduction of cardiac
mortality in chronically transfused TM patientsIntroduction
In 2004 seven Italian centers reported survival
data for patients with thalassemia major (TM) and showed that heart disease due
to iron overload was the most common cause of death [1]. In the same years the
accurate and noninvasive assessment of cardiac siderosis was made possible in
Italy by the introduction of the T2* cardiovascular magnetic resonance (CMR)
[2].
We aimed to evaluate if the deployment of T2*
CMR had an impact on the mortality rate.
Methods
Four centers contributed to the present study,
updating the data of the enrolled patients until August 31, 2010. For the
patients who died, the date of the death represented the end of the study. 577
patients (264 females and 313 males) were included. All patients were born on or after January 1, 1960 and mean age at the
follow-up was 28.04 ± 10.88 years (median 29.52 years). Patients had been
diagnosed as being affected by TM at a mean age of 10.95 ± 16.05 months (median
7.49 months). Patients were uniformly treated. Mean transfusion starting age
was 1.20 ± 1.59 years (median 0.8 years).
Results
One-hundred and fifty-nine (27.6%) patients
died, 124 of whom (77.9%) died before the year 2000.
Dead patients were significantly younger and
they were more frequently males. Dead patients started chelation therapy
significantly later. Dead patients showed an higher frequency of HIV,
arrhythmias and heart failure (see Table).
According to the Cox model, the following
variables were identified as significant univariate prognosticators for the
death: male sex (HR=1.87, 95%CI=1.34-2.60, P<0.0001), HIV (HR=2.55,
95%CI=1.25-5.20, P=0.010) and heart failure (HR=8.86, 95%CI=6.37-12.31,
P<0.0001).
MRI was not performed in 406 patients (70.4%)
and no patient had been scanned before his/her death. Among the survivors, MRI
was not performed in the 59% of the cases (P<0.0001). The absence of an MRI
scan was a significant univariate prognosticator for death (HR=43.25,
95%CI=11.32-165.33, P<0.0001).
The study was restricted to the patients dead
after 2004 (19/159=12%) or followed until August 2010 (N=357). In this subgroup
of 376 patients, MRI was not performed in the 52.4% of the survivors and in all
dead patients (P<0.0001). The absence of a MRI exam was reconfirmed as a
strong predictive factor for death (HR=49.37, 95%CI=1.08-2263.24, P=0.046). The
Kaplan–Meier curve is showed in the Figure. The log-rank test revealed a
significant difference in the curves (P<0.0001).
Conclusions
Our data suggests that the use of T2* CMR, that
enables individually tailored chelation regimes reducing the likelihood of
developing decompensated cardiac failure, allowed the reduction of cardiac
mortality in chronically transfused TM patients.
Acknowledgements
We thank all the
colleagues of the MIOT Network (https://miot.ftgm.it).
The MIOT project
receives “no-profit support” from industrial sponsorships (Chiesi Farmaceutici
S.p.A. and ApoPharma Inc.).
References
[1] Borgna et al. Haematologica 2004;89:1187-93.
[2] Pepe A et al. JMRI 2006;23:662-8.